Needle and Syringe Programs (NSPs) have long sat at the frontline of Australia’s response to Hepatitis C. While major medical advances have transformed treatment outcomes in recent years, the everyday harm reduction work of NSPs remains one of the most important tools in preventing transmission and connecting people with care.
At their core, NSPs provide access to sterile injecting equipment, helping reduce the risk of blood-borne virus transmission through needle re-use and syringe sharing. Recent Tasmanian survey data shows that these risks remain, and there is work to be done. Needle re-use sat at 23 per cent in 2024, while receptive syringe sharing rose slightly to 18 per cent from previous years. These numbers are a reminder that harm reduction work is ongoing.
For many people, NSPs are also one of the few accessible and non-judgmental entry points into healthcare. Workers provide information about hepatitis C testing, treatment pathways and free clinics, often supporting people who may not otherwise engage with mainstream health services.
The Australian NSP national data report shows that in Tasmania, hepatitis C testing fluctuates and has reduced in recent years, despite injecting drug use remaining a primary risk factor. There are often no obvious signs or symptoms in the early stages of hepatitis C which can lead to many people remaining undiagnosed and the potential for long-term health complications like liver disease and liver cancer from chronic hepatitis C. This is why early and routine testing remains vital for your health.
The role of NSPs extends beyond equipment distribution. They are spaces where trust is built, stigma is reduced, and health conversations happen without fear of judgement. As hepatitis C rates continue to decline across Australia, NSPs still remain an essential program, not only in preventing transmission, but in ensuring people have the knowledge, support and access needed to stay healthy.
